Joshua Fitch, Senior Editor

Currently, there are no treatments for the serious, rare pediatric disease.

From 2017-2018, antiviral treatment of hospitalized children with influenza ranged from 70%-86%. In the 2023-2024 season, it was less than 60%.

Paul Kruszka, MD, MPH, FACMG, chief medical officer of GeneDx, joined us to provide background of whole genome sequencing and its benefits.

Once-daily icotrokinra versus placebo demonstrated clinically significant skin clearance in those with moderate-to-severe plaque psoriasis.

A further understanding of the role SARS-CoV-2 plays in T2D incidence can add an important component to benefit and risk considerations to prevent COVID-19.

Stephanie Anne Deutsch, MD, MS, MSCR, FAAP, joined us to discuss a new study that highlighted SUID among infants who were prenatally substance exposed.

H. Westley Phillips, MD, explains why awareness and availability of epilepsy surgery is important for pediatric providers among drug-resistant epilepsy patients.

Results demonstrated that daily oral infigratinib treatment led to increases in annualized height velocity and improvement in body proportionality.

David Turkewitz, MD, explains how getting involved in the community to advocate for SUID awareness can make a difference in outcomes for the infant population.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from last week, all in one place.

With this expanded FDA clearance, the wearable becomes the first FDA-cleared, non-drug therapy to treat acute migraines in children.

The application indication is for adults and pediatric patients aged 12 years and older with CSU whose disease is not adequately controlled with H1 antihistamines.

H. Westley Phillips, MD, joined us to provide clinical pearls regarding the early identification of drug-resistant epilepsy patients in the primary care setting.

With the decision, Kebilidi becomes the first FDA-approved gene therapy for AADC deficiency, and is indicated for adult and pediatric patients.

A discussion of tips and recommendations general providers can use when evaluating ADHD in pediatric patients.

A target action date for potential approval of prademagene zamikeracel (pz-cel) has been set for April 29, 2025.

The primary endpoint of the study was survival free of BPD at 36 weeks' postmenstrual age.

A key update includes providing CPR with rescue breaths and chest compressions to all persons in cardiac arrest after water removal.

Data stems from the first 4 patients dosed in a low-dose cohort of an ongoing phase 1/2 open-label trial.

The initiation of a phase 2 study of the investigational 31-valent pneumococcal conjugate vaccine is expected by the end of January 2025.

In this video discussion, David Turkewitz, MD, offers clinical pearls to reduce the risk of SIDS and reviews the updated 2022 guidelines from the AAP.

At any point in the study, adolescents who used cannabis reported a greater number of psychosis spectrum symptoms.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from last week, all in one place.

Rakesh Jain, MD, MPH, notes that with increasing ADHD trends, a newly-available and FDA-approved non-stimulant tool can help treat more patients.

The study outcomes were estimated IMD cases and deaths averted by MenACWY vaccination in adolescents and adults aged 11 to 23 years.

The federal agency has not raised any concerns regarding safety and efficacy of tapinarof cream, 1%.

Severe outcomes among children with pneumonia were uncommon, regardless of whether antibiotics were received based on study results.

Application acceptance was based on positive results with monthly and bi-monthly dosing data from a phase 3 trial.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from last week, all in one place.

Jain breaks down key benefits of clonidine hydrochloride (ONYDA XR; Tris Pharma) to treat ADHD among patients aged 6 years and older.